Toggle Health Problems and D

COVID-19 1.8 X more likely if proton pump inhibitor (which decreases Mg needed for Vitamin D) – Aug 2020

Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching

Gut 2020;0:1–9. doi:10.1136/gutjnl-2020-322248
Seung Won Lee1, Eun Kyo Ha2, Abdullah Özgür Yeniova3, Sung Yong Moon1, So Young Kim4, Hyun Yong Koh5, Jee Myung Yang6, Su Jin Jeong7, Sun Joon Moon8, Joo Young Cho9, In Kyung Yoo9, http://orcid.org/0000-0003-1628-9948Dong Keon Yon7,10

 Download the PDF from Vitamin D Life

Objective The adverse effects of proton pump inhibitors (PPIs) have been documented for pneumonia; however, there is no consensus regarding whether the use of PPIs might be harmful regarding the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this regard, we aimed to measure the potential associations of the current use of PPIs with the infection rates of COVID-19 among patients who underwent SARS-CoV-2 testing.

Design Data were derived from a Korean nationwide cohort study with propensity score matching. We included 132 316 patients older than 18 years who tested for SARS-CoV-2 between 1 January and 15 May 2020. Endpoints were SARS-CoV-2 positivity (primary) and severe clinical outcomes of COVID-19 (secondary: admission to intensive care unit, administration of invasive ventilation or death).

Results In the entire cohort, there were 111 911 non-users, 14 163 current PPI users and 6242 past PPI users. After propensity score matching, the SARS-CoV-2 test positivity rate was not associated with the current or past use of PPIs. Among patients with confirmed COVID-19, the current use of PPIs conferred a 79% greater risk of severe clinical outcomes of COVID-19, while the relationship with the past use of PPIs remained insignificant. Current PPI use starting within the previous 30 days was associated with a 90% increased risk of severe clinical outcomes of COVID-19.

Conclusion Patients taking PPIs are at increased risk for severe clinical outcomes of COVID-19 but not susceptible to SARS-CoV-2 infection. This suggests that physicians need to assess benefit–risk assessments in the management of acid-related diseases amid the COVID-19 pandemic.

Created by admin. Last Modification: Friday August 7, 2020 18:59:43 GMT-0000 by admin. (Version 9)

Attached files

ID Name Comment Uploaded Size Downloads
14138 OP-GAST140054 243..253 - gou054.pdf admin 07 Aug, 2020 18:53 865.20 Kb 75
14135 Gut BMJ Covid and PPI 2020.pdf PDF 2020 admin 07 Aug, 2020 17:08 1.33 Mb 69
See any problem with this page? Report it (FINALLY WORKS)